Dupixent® (dupilumab) u.s. label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement

Data included from first and only phase 3 trial specifically evaluating a biologic in this difficult-to-treat population phase 3 trial showed more than twice as many patients treated with dupixent achieved clear or almost clear skin and nearly four times as many had improvement in itch, compared with placebo tarrytown, n.y. and paris, jan. 16, 2024 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the u.s. food and drug administration (fda) has updated the label for dupixent® (dupilumab) in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.
REGN Ratings Summary
REGN Quant Ranking